Data / Form D filings / Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc.: Form D filing
Aurinia Pharmaceuticals Inc., a biotechnology company in Victoria, British Columbia, Canada, filed a Form D with the SEC in 2014. The latest, on February 28, 2014, reports $52 million sold of a $52 million offering to 22 investors.
Find out what Aurinia Pharmaceuticals Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- #1203-4464 MARKHAM STREET, Victoria, British Columbia, Canada, V8Z 7
- Phone
- (250) 708-4272
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Alberta, Canada
- Year incorporated
- 2009
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1600620
The full lists. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 28, 2014 | New notice | $52,000,000 | $52,000,000 | $0 | 22 | Feb 14, 2014 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Kurt von M. Emster | Director | |
| Benjamin M. Rovinski | Director | |
| Chris M. Kim | Director | |
| Donald M. Wyatt | Director | |
| Stephen W. Zaruby | Executive Officer, Director | |
| Michael M. Martin | Executive Officer, Director | |
| Dennis M. Bourgeault | Executive Officer | |
| Daniel M. Park | Director | |
| Richard M. Glickman | Executive Officer, Director | |
| Peter M. Wijngaard | Director |
Every Form D from the week of Feb 24, 2014 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Aurinia Pharmaceuticals Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.